Treatment Algorithms for Systemic Sclerosis According to Experts.
Identifieur interne : 000083 ( PubMed/Checkpoint ); précédent : 000082; suivant : 000084Treatment Algorithms for Systemic Sclerosis According to Experts.
Auteurs : Andreu Fernández-Codina [Espagne] ; Kyle M. Walker [Canada] ; Janet E. Pope [Canada]Source :
- Arthritis & rheumatology (Hoboken, N.J.) [ 2326-5205 ] ; 2018.
Descripteurs français
- KwdFr :
- Acide mycophénolique (usage thérapeutique), Algorithmes, Antagonistes des récepteurs aux angiotensines (usage thérapeutique), Antagonistes des récepteurs de l'endothéline (usage thérapeutique), Anticorps monoclonaux humanisés (usage thérapeutique), Antirhumatismaux (usage thérapeutique), Arthrite (traitement médicamenteux), Arthrite (étiologie), Canaux calciques (usage thérapeutique), Cyclophosphamide (usage thérapeutique), Glucocorticoïdes (usage thérapeutique), Humains, Hydroxychloroquine, Hypertension pulmonaire (traitement médicamenteux), Hypertension pulmonaire (étiologie), Immunosuppresseurs (usage thérapeutique), Inhibiteurs de l'enzyme de conversion de l'angiotensine (usage thérapeutique), Inhibiteurs de la phosphodiestérase-5 (usage thérapeutique), Maladie de Raynaud (traitement médicamenteux), Maladie de Raynaud (étiologie), Maladies du rein (traitement médicamenteux), Maladies du rein (étiologie), Méthotrexate (usage thérapeutique), Pneumopathies interstitielles (traitement médicamenteux), Pneumopathies interstitielles (étiologie), Prostaglandines (usage thérapeutique), Rituximab (usage thérapeutique), Sclérodermie systémique (), Sclérodermie systémique (traitement médicamenteux).
- MESH :
- traitement médicamenteux : Arthrite, Hypertension pulmonaire, Maladie de Raynaud, Maladies du rein, Pneumopathies interstitielles, Sclérodermie systémique.
- usage thérapeutique : Acide mycophénolique, Antagonistes des récepteurs aux angiotensines, Antagonistes des récepteurs de l'endothéline, Anticorps monoclonaux humanisés, Antirhumatismaux, Canaux calciques, Cyclophosphamide, Glucocorticoïdes, Immunosuppresseurs, Inhibiteurs de l'enzyme de conversion de l'angiotensine, Inhibiteurs de la phosphodiestérase-5, Méthotrexate, Prostaglandines, Rituximab.
- étiologie : Arthrite, Hypertension pulmonaire, Maladie de Raynaud, Maladies du rein, Pneumopathies interstitielles.
- Algorithmes, Humains, Hydroxychloroquine, Sclérodermie systémique.
English descriptors
- KwdEn :
- Algorithms, Angiotensin Receptor Antagonists (therapeutic use), Angiotensin-Converting Enzyme Inhibitors (therapeutic use), Antibodies, Monoclonal, Humanized (therapeutic use), Antirheumatic Agents (therapeutic use), Arthritis (drug therapy), Arthritis (etiology), Calcium Channels (therapeutic use), Cyclophosphamide (therapeutic use), Endothelin Receptor Antagonists (therapeutic use), Glucocorticoids (therapeutic use), Humans, Hydroxychloroquine, Hypertension, Pulmonary (drug therapy), Hypertension, Pulmonary (etiology), Immunosuppressive Agents (therapeutic use), Kidney Diseases (drug therapy), Kidney Diseases (etiology), Lung Diseases, Interstitial (drug therapy), Lung Diseases, Interstitial (etiology), Methotrexate (therapeutic use), Mycophenolic Acid (therapeutic use), Phosphodiesterase 5 Inhibitors (therapeutic use), Prostaglandins (therapeutic use), Raynaud Disease (drug therapy), Raynaud Disease (etiology), Rituximab (therapeutic use), Scleroderma, Systemic (complications), Scleroderma, Systemic (drug therapy).
- MESH :
- chemical , therapeutic use : Angiotensin Receptor Antagonists, Angiotensin-Converting Enzyme Inhibitors, Antibodies, Monoclonal, Humanized, Antirheumatic Agents, Calcium Channels, Cyclophosphamide, Endothelin Receptor Antagonists, Glucocorticoids, Immunosuppressive Agents, Methotrexate, Mycophenolic Acid, Phosphodiesterase 5 Inhibitors, Prostaglandins, Rituximab.
- complications : Scleroderma, Systemic.
- drug therapy : Arthritis, Hypertension, Pulmonary, Kidney Diseases, Lung Diseases, Interstitial, Raynaud Disease, Scleroderma, Systemic.
- etiology : Arthritis, Hypertension, Pulmonary, Kidney Diseases, Lung Diseases, Interstitial, Raynaud Disease.
- Algorithms, Humans, Hydroxychloroquine.
Abstract
There is a lack of agreement regarding treatment for many aspects of systemic sclerosis (SSc). We undertook this study to generate SSc treatment algorithms endorsed by a high percentage of SSc experts.
DOI: 10.1002/art.40560
PubMed: 29781586
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:29781586Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Treatment Algorithms for Systemic Sclerosis According to Experts.</title><author><name sortKey="Fernandez Codina, Andreu" sort="Fernandez Codina, Andreu" uniqKey="Fernandez Codina A" first="Andreu" last="Fernández-Codina">Andreu Fernández-Codina</name><affiliation wicri:level="3"><nlm:affiliation>University of Western Ontario, London, Ontario, Canada, and Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>University of Western Ontario, London, Ontario, Canada, and Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona</wicri:regionArea><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author><author><name sortKey="Walker, Kyle M" sort="Walker, Kyle M" uniqKey="Walker K" first="Kyle M" last="Walker">Kyle M. Walker</name><affiliation wicri:level="1"><nlm:affiliation>The Ottawa Hospital, University of Ottawa, Ottawa, Ontario, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>The Ottawa Hospital, University of Ottawa, Ottawa, Ontario</wicri:regionArea><wicri:noRegion>Ontario</wicri:noRegion></affiliation></author><author><name sortKey="Pope, Janet E" sort="Pope, Janet E" uniqKey="Pope J" first="Janet E" last="Pope">Janet E. Pope</name><affiliation wicri:level="1"><nlm:affiliation>University of Western Ontario, London, Ontario, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>University of Western Ontario, London, Ontario</wicri:regionArea><wicri:noRegion>Ontario</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2018">2018</date><idno type="RBID">pubmed:29781586</idno><idno type="pmid">29781586</idno><idno type="doi">10.1002/art.40560</idno><idno type="wicri:Area/PubMed/Corpus">000107</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000107</idno><idno type="wicri:Area/PubMed/Curation">000107</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000107</idno><idno type="wicri:Area/PubMed/Checkpoint">000083</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000083</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Treatment Algorithms for Systemic Sclerosis According to Experts.</title><author><name sortKey="Fernandez Codina, Andreu" sort="Fernandez Codina, Andreu" uniqKey="Fernandez Codina A" first="Andreu" last="Fernández-Codina">Andreu Fernández-Codina</name><affiliation wicri:level="3"><nlm:affiliation>University of Western Ontario, London, Ontario, Canada, and Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>University of Western Ontario, London, Ontario, Canada, and Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona</wicri:regionArea><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author><author><name sortKey="Walker, Kyle M" sort="Walker, Kyle M" uniqKey="Walker K" first="Kyle M" last="Walker">Kyle M. Walker</name><affiliation wicri:level="1"><nlm:affiliation>The Ottawa Hospital, University of Ottawa, Ottawa, Ontario, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>The Ottawa Hospital, University of Ottawa, Ottawa, Ontario</wicri:regionArea><wicri:noRegion>Ontario</wicri:noRegion></affiliation></author><author><name sortKey="Pope, Janet E" sort="Pope, Janet E" uniqKey="Pope J" first="Janet E" last="Pope">Janet E. Pope</name><affiliation wicri:level="1"><nlm:affiliation>University of Western Ontario, London, Ontario, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>University of Western Ontario, London, Ontario</wicri:regionArea><wicri:noRegion>Ontario</wicri:noRegion></affiliation></author></analytic><series><title level="j">Arthritis & rheumatology (Hoboken, N.J.)</title><idno type="eISSN">2326-5205</idno><imprint><date when="2018" type="published">2018</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Algorithms</term><term>Angiotensin Receptor Antagonists (therapeutic use)</term><term>Angiotensin-Converting Enzyme Inhibitors (therapeutic use)</term><term>Antibodies, Monoclonal, Humanized (therapeutic use)</term><term>Antirheumatic Agents (therapeutic use)</term><term>Arthritis (drug therapy)</term><term>Arthritis (etiology)</term><term>Calcium Channels (therapeutic use)</term><term>Cyclophosphamide (therapeutic use)</term><term>Endothelin Receptor Antagonists (therapeutic use)</term><term>Glucocorticoids (therapeutic use)</term><term>Humans</term><term>Hydroxychloroquine</term><term>Hypertension, Pulmonary (drug therapy)</term><term>Hypertension, Pulmonary (etiology)</term><term>Immunosuppressive Agents (therapeutic use)</term><term>Kidney Diseases (drug therapy)</term><term>Kidney Diseases (etiology)</term><term>Lung Diseases, Interstitial (drug therapy)</term><term>Lung Diseases, Interstitial (etiology)</term><term>Methotrexate (therapeutic use)</term><term>Mycophenolic Acid (therapeutic use)</term><term>Phosphodiesterase 5 Inhibitors (therapeutic use)</term><term>Prostaglandins (therapeutic use)</term><term>Raynaud Disease (drug therapy)</term><term>Raynaud Disease (etiology)</term><term>Rituximab (therapeutic use)</term><term>Scleroderma, Systemic (complications)</term><term>Scleroderma, Systemic (drug therapy)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Acide mycophénolique (usage thérapeutique)</term><term>Algorithmes</term><term>Antagonistes des récepteurs aux angiotensines (usage thérapeutique)</term><term>Antagonistes des récepteurs de l'endothéline (usage thérapeutique)</term><term>Anticorps monoclonaux humanisés (usage thérapeutique)</term><term>Antirhumatismaux (usage thérapeutique)</term><term>Arthrite (traitement médicamenteux)</term><term>Arthrite (étiologie)</term><term>Canaux calciques (usage thérapeutique)</term><term>Cyclophosphamide (usage thérapeutique)</term><term>Glucocorticoïdes (usage thérapeutique)</term><term>Humains</term><term>Hydroxychloroquine</term><term>Hypertension pulmonaire (traitement médicamenteux)</term><term>Hypertension pulmonaire (étiologie)</term><term>Immunosuppresseurs (usage thérapeutique)</term><term>Inhibiteurs de l'enzyme de conversion de l'angiotensine (usage thérapeutique)</term><term>Inhibiteurs de la phosphodiestérase-5 (usage thérapeutique)</term><term>Maladie de Raynaud (traitement médicamenteux)</term><term>Maladie de Raynaud (étiologie)</term><term>Maladies du rein (traitement médicamenteux)</term><term>Maladies du rein (étiologie)</term><term>Méthotrexate (usage thérapeutique)</term><term>Pneumopathies interstitielles (traitement médicamenteux)</term><term>Pneumopathies interstitielles (étiologie)</term><term>Prostaglandines (usage thérapeutique)</term><term>Rituximab (usage thérapeutique)</term><term>Sclérodermie systémique ()</term><term>Sclérodermie systémique (traitement médicamenteux)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Angiotensin Receptor Antagonists</term><term>Angiotensin-Converting Enzyme Inhibitors</term><term>Antibodies, Monoclonal, Humanized</term><term>Antirheumatic Agents</term><term>Calcium Channels</term><term>Cyclophosphamide</term><term>Endothelin Receptor Antagonists</term><term>Glucocorticoids</term><term>Immunosuppressive Agents</term><term>Methotrexate</term><term>Mycophenolic Acid</term><term>Phosphodiesterase 5 Inhibitors</term><term>Prostaglandins</term><term>Rituximab</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Scleroderma, Systemic</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Arthritis</term><term>Hypertension, Pulmonary</term><term>Kidney Diseases</term><term>Lung Diseases, Interstitial</term><term>Raynaud Disease</term><term>Scleroderma, Systemic</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Arthritis</term><term>Hypertension, Pulmonary</term><term>Kidney Diseases</term><term>Lung Diseases, Interstitial</term><term>Raynaud Disease</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Arthrite</term><term>Hypertension pulmonaire</term><term>Maladie de Raynaud</term><term>Maladies du rein</term><term>Pneumopathies interstitielles</term><term>Sclérodermie systémique</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Acide mycophénolique</term><term>Antagonistes des récepteurs aux angiotensines</term><term>Antagonistes des récepteurs de l'endothéline</term><term>Anticorps monoclonaux humanisés</term><term>Antirhumatismaux</term><term>Canaux calciques</term><term>Cyclophosphamide</term><term>Glucocorticoïdes</term><term>Immunosuppresseurs</term><term>Inhibiteurs de l'enzyme de conversion de l'angiotensine</term><term>Inhibiteurs de la phosphodiestérase-5</term><term>Méthotrexate</term><term>Prostaglandines</term><term>Rituximab</term></keywords><keywords scheme="MESH" qualifier="étiologie" xml:lang="fr"><term>Arthrite</term><term>Hypertension pulmonaire</term><term>Maladie de Raynaud</term><term>Maladies du rein</term><term>Pneumopathies interstitielles</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Algorithms</term><term>Humans</term><term>Hydroxychloroquine</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Algorithmes</term><term>Humains</term><term>Hydroxychloroquine</term><term>Sclérodermie systémique</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">There is a lack of agreement regarding treatment for many aspects of systemic sclerosis (SSc). We undertook this study to generate SSc treatment algorithms endorsed by a high percentage of SSc experts.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">29781586</PMID><DateCompleted><Year>2019</Year><Month>07</Month><Day>22</Day></DateCompleted><DateRevised><Year>2019</Year><Month>07</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2326-5205</ISSN><JournalIssue CitedMedium="Internet"><Volume>70</Volume><Issue>11</Issue><PubDate><Year>2018</Year><Month>11</Month></PubDate></JournalIssue><Title>Arthritis & rheumatology (Hoboken, N.J.)</Title></Journal><ArticleTitle>Treatment Algorithms for Systemic Sclerosis According to Experts.</ArticleTitle><Pagination><MedlinePgn>1820-1828</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/art.40560</ELocationID><Abstract><AbstractText Label="OBJECTIVE">There is a lack of agreement regarding treatment for many aspects of systemic sclerosis (SSc). We undertook this study to generate SSc treatment algorithms endorsed by a high percentage of SSc experts.</AbstractText><AbstractText Label="METHODS">Experts from the Scleroderma Clinical Trials Consortium and the Canadian Scleroderma Research group (n = 170) were asked whether they agreed with SSc algorithms from 2012. Two consensus rounds refined agreement; 62, 54, and 48 experts (36%, 32%, and 28%, respectively) completed the first, second, and third surveys, respectively.</AbstractText><AbstractText Label="RESULTS">For treatment of scleroderma renal crisis, 81% of experts agreed (first-, second-, and third-line treatments were angiotensin-converting enzyme inhibitors, then adding calcium-channel blockers [CCBs], then adding angiotensin receptor blockers [ARBs], respectively). For pulmonary arterial hypertension (PAH), 81% of experts agreed (for mild PAH, treatments were phosphodiesterase 5 [PDE5] inhibitors, then endothelin receptor antagonists plus PDE5 inhibitors, then prostanoids, respectively; for severe PAH, prostanoids were first-line treatment). For mild Raynaud's phenomenon (RP), 79% of experts agreed (treatments were CCBs, then adding PDE5 inhibitors, then ARBs or switching to another CCB, respectively; after the third line of treatment, mild RP was deemed severe). For severe RP, the first- through fourth-line treatments were CCBs, then adding PDE5 inhibitors or prostanoids, then adding PDE5 inhibitors (if not added as second-line treatment) or prostanoids (if not added as second-line treatment), then switching to another CCB, respectively. For active treatment of digital ulcers, 66% of experts agreed (first- and second-line treatments were CCBs and PDE5 inhibitors, respectively). For interstitial lung disease, 69% of experts agreed (for induction therapy, treatments were mycophenolate mofetil [MMF], intravenous cyclophosphamide [IV CYC], and rituximab, respectively; for maintenance, first-line treatment was MMF). For skin involvement, 71% of experts agreed (for a modified Rodnan skin thickness score [MRSS] of 24, first- and second-line treatments were methotrexate [MTX] and MMF, respectively; for an MRSS of 32, first- through fourth-line treatments were MMF, MTX, IV CYC, and hematopoietic stem cell transplantation, respectively). For inflammatory arthritis, 79% of experts agreed (first- through fourth-line treatments were MTX, low-dose glucocorticoids, hydroxychloroquine, and rituximab or tocilizumab, respectively). Algorithms for cardiac and gastrointestinal involvement had ≥75% agreement.</AbstractText><AbstractText Label="CONCLUSION">Total agreement for SSc algorithms was considerable. These algorithms may guide treatment.</AbstractText><CopyrightInformation>© 2018, American College of Rheumatology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fernández-Codina</LastName><ForeName>Andreu</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>University of Western Ontario, London, Ontario, Canada, and Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Walker</LastName><ForeName>Kyle M</ForeName><Initials>KM</Initials><AffiliationInfo><Affiliation>The Ottawa Hospital, University of Ottawa, Ottawa, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pope</LastName><ForeName>Janet E</ForeName><Initials>JE</Initials><AffiliationInfo><Affiliation>University of Western Ontario, London, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Scleroderma Algorithm Group</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016446">Consensus Development Conference</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>09</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Arthritis Rheumatol</MedlineTA><NlmUniqueID>101623795</NlmUniqueID><ISSNLinking>2326-5191</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057911">Angiotensin Receptor Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000806">Angiotensin-Converting Enzyme Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018501">Antirheumatic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015220">Calcium Channels</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D065128">Endothelin Receptor Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005938">Glucocorticoids</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007166">Immunosuppressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058986">Phosphodiesterase 5 Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011453">Prostaglandins</NameOfSubstance></Chemical><Chemical><RegistryNumber>4F4X42SYQ6</RegistryNumber><NameOfSubstance UI="D000069283">Rituximab</NameOfSubstance></Chemical><Chemical><RegistryNumber>4QWG6N8QKH</RegistryNumber><NameOfSubstance UI="D006886">Hydroxychloroquine</NameOfSubstance></Chemical><Chemical><RegistryNumber>8N3DW7272P</RegistryNumber><NameOfSubstance UI="D003520">Cyclophosphamide</NameOfSubstance></Chemical><Chemical><RegistryNumber>HU9DX48N0T</RegistryNumber><NameOfSubstance UI="D009173">Mycophenolic Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>I031V2H011</RegistryNumber><NameOfSubstance UI="C502936">tocilizumab</NameOfSubstance></Chemical><Chemical><RegistryNumber>YL5FZ2Y5U1</RegistryNumber><NameOfSubstance UI="D008727">Methotrexate</NameOfSubstance></Chemical></ChemicalList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000465" MajorTopicYN="Y">Algorithms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057911" MajorTopicYN="N">Angiotensin Receptor Antagonists</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000806" MajorTopicYN="N">Angiotensin-Converting Enzyme Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D061067" MajorTopicYN="N">Antibodies, Monoclonal, Humanized</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018501" MajorTopicYN="N">Antirheumatic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001168" MajorTopicYN="N">Arthritis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015220" MajorTopicYN="N">Calcium Channels</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003520" MajorTopicYN="N">Cyclophosphamide</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D065128" MajorTopicYN="N">Endothelin Receptor Antagonists</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005938" MajorTopicYN="N">Glucocorticoids</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006886" MajorTopicYN="N">Hydroxychloroquine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006976" MajorTopicYN="N">Hypertension, Pulmonary</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007166" MajorTopicYN="N">Immunosuppressive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007674" MajorTopicYN="N">Kidney Diseases</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017563" MajorTopicYN="N">Lung Diseases, Interstitial</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008727" MajorTopicYN="N">Methotrexate</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009173" MajorTopicYN="N">Mycophenolic Acid</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058986" MajorTopicYN="N">Phosphodiesterase 5 Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011453" MajorTopicYN="N">Prostaglandins</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011928" MajorTopicYN="N">Raynaud Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000069283" MajorTopicYN="N">Rituximab</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012595" MajorTopicYN="N">Scleroderma, Systemic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>01</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>05</Month><Day>08</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>5</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>7</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>5</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29781586</ArticleId><ArticleId IdType="doi">10.1002/art.40560</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Canada</li><li>Espagne</li></country><region><li>Catalogne</li></region><settlement><li>Barcelone</li></settlement></list><tree><country name="Espagne"><region name="Catalogne"><name sortKey="Fernandez Codina, Andreu" sort="Fernandez Codina, Andreu" uniqKey="Fernandez Codina A" first="Andreu" last="Fernández-Codina">Andreu Fernández-Codina</name></region></country><country name="Canada"><noRegion><name sortKey="Walker, Kyle M" sort="Walker, Kyle M" uniqKey="Walker K" first="Kyle M" last="Walker">Kyle M. Walker</name></noRegion><name sortKey="Pope, Janet E" sort="Pope, Janet E" uniqKey="Pope J" first="Janet E" last="Pope">Janet E. Pope</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000083 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 000083 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:29781586
|texte= Treatment Algorithms for Systemic Sclerosis According to Experts.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:29781586" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a ChloroquineV1
| This area was generated with Dilib version V0.6.33. |  |